Profile

Phoenix A. Ho, MD

Phoenix A. Ho, MD

Hematology-Oncology

On staff since July 2009

Academic Title: Assistant Professor

"Children are remarkable people; it's an honor to take care of them and witness the strength, spirit, resilience and sense of humor with which they face adversity. At Children's, I'm privileged to be part of a comprehensive team, all working together to provide excellent care for our patients and their families during difficult times."

Phoenix A. Ho, MD, is attending physician in Hematology / Oncology at Seattle Childrens Hospital, and acting assistant professor in the Department of Pediatrics at the University of Washington School of Medicine.

Dr. Ho is also is an associate in clinical research at the Fred Hutchinson Cancer Research Center (FHCRC), where he studies myeloid leukemia in the laboratory of Dr. Soheil Meshinchi and myelodysplastic syndrome / inherited bone marrow failure in the lab of Dr. Akiko Shimamura. His goal is to translate his research into new treatments and better outcomes for children with bone marrow failure and leukemia.

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

Northeastern Ohio Universities College of Medicine, Rootstown

Residency

Pediatrics, Yale-New Haven Hospital , New Haven

Fellowship

Hematology, University of Washington School of Medicine, Seattle

Awards and Honors

Award Name Award Description Awarded By Award Date
ALSF Young Investigator Award Alex's Lemonade Stand Foundation July 1, 2012 - June 30, 2014
MCSF AML Research Award Mary Claire Satterly Foundation Jan. 1, 2010
Young Investigator Award - Journal of Clinical Oncology Journal of Clinical Oncology Jan. 1, 2009
Alex's Lemonade Stand Foundation Young Investigator Alex's Lemonade Stand Foundation

Publications

  • Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch B, Raimondi SC, Gamis AS, Meshinchi S
    The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: Report from the Children's Oncology Group.
    Pediatric blood & cancer , 2014 Jan. : 61(1)81-8
  • Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S
    High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
    British journal of haematology , 2013 Sept. : 162(5)670-7
  • Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S
    Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.
    Blood , 2012 Aug. 23 : 120(8)1581-8
  • Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S
    Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
    Blood , 2012 Apr, 19 : 119(16)3705-11
  • Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S
    Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
    Blood , 2011 Oct. 27 : 118(17)4561-6
  • Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S
    Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Pediatric blood & cancer , 2011 Aug. : 57(2)204-9
  • Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, Alonzo TA, Meshinchi S
    WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Feb. 20 : 704-11
  • Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK, Tenen DG, Behre G
    C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.
    Blood , 2010 Dec. 16 : 5638-49
  • Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S
    Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
    Blood , 2010 Aug. 5 : 702-10
  • Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S
    Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
    Blood , 2010 Mar. 25 : 2372-9
  • Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S
    Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
    Blood , 2009 June 25 : 6558-66

Research Funding

Grant Title Grantor Amount Award Date
Exploiting WT1 Genomic Alterations for Target Identification and Minimal Residual Disease Monitoring in Pediatric AML Alex's Lemonade Stand Foundation $50,000 (annual) July 1, 2012 - June 30, 2014
SHIP and WT1 alterations as markers of PI3K/Akt activation in pediatric AML Mary Claire Satterly Foundation $50,000.00 Nov. 1, 2010
Implications of s-SHIP Expression and SHIP Alterations in AML American Society of Clinical Oncology Cancer Foundation $50,000.00 July 1, 2009
Implications of s-SHIP Expression and SHIP Alterations in AML University of Washington Child Health Research Center $240,000.00 July 1, 2009